Immix Biopharma (IMMX) Long-Term Deferred Tax (2022 - 2026)

Immix Biopharma (IMMX) reported Long-Term Deferred Tax of $164723.0 for Q1 2026, up 75.93% sequentially from $93630.0 in Q4 2025.

Immix Biopharma (IMMX) Long-Term Deferred Tax (2022 - 2026) Analysis & Trends

Immix Biopharma (IMMX) has 4 years of Long-Term Deferred Tax data on file, last reported at $164723.0 in Q1 2026.

For the quarter ending Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $164723.0; the trailing twelve-month figure through Mar 2026 stood at $164723.0 (changed N/A YoY), and the FY2025 full-year result was $93630.0, changed N/A from the prior year.
Long-Term Deferred Tax climbed to $164723.0 in Q1 2026, from $93630.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $164723.0 in Q1 2026 to a low of $6724.0 in Q4 2022.
A 4-year average of $95766.8 and a median of $102118.0 in 2025 frame the typical range for Long-Term Deferred Tax.
Peak annual rise in Long-Term Deferred Tax reached 1197.28% in 2023, while the deepest fall reached 1197.28% in 2023.
Tracing IMMX's Long-Term Deferred Tax over 4 years: stood at $6724.0 in 2022, then surged by 1197.28% to $87229.0 in 2023, then rose by 7.34% to $93630.0 in 2025, then soared by 75.93% to $164723.0 in 2026.
Business Quant data shows IMMX's Long-Term Deferred Tax at $164723.0 in Q1 2026, $93630.0 in Q4 2025, and $111689.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immix Biopharma	487.25 Mn	487.25 Mn	-

Download Data